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1.9 Abstract: 
Heart failure is a common, costly and burdensome condition for individuals, health care systems and 
societies. Multiple innovations, both pharmacological and non-pharmacological, have transformed care 
for millions around the world. Ventricular assist devices (VADs), as one of these new technologies, have 
saved many lives and bridged many to transplantation, while improving quality of life. VAD registry and 
clinical trial data are providing a roadmap for clinicians in their effective and most appropriate use, but 
the implementation of evidence based interventions requires consideration of patient, provider and 
system characteristics. 
Australia supports a system of universal health coverage, yet has challenges in ensuring equity of access 
to care. Complex and fragmented funding models challenge an integrated understanding of the total 
costs associated with care pathways. A number of regulatory, and comprehensive health technology 
assessment processes inform policy and funding, and costing methods specific to local care models, are 
critical to inform health services planning. 
As health care systems around the world examine value-based funding models, understanding patient 
preferences is also important. Many clinical trials do not include comprehensive economic analyses nor 
consider incentives for, and barriers to achieving access across health systems and funding models. 
Communicating the value of an intervention to improve quality of life, requires consideration of patient, 
provider and population preferences. 
This thesis is comprised of a number of discrete yet linked studies that sought to address the following 
questions, 
1. How can linked data be used to establish costs and hospitalisation across different institutions 
in the years preceding and following VAD implant? 
2. What is the relationship between VAD therapy as a bridge to transplant and  overall heart 
failure hospitalisation and management costs compared with medical management? 
3. What are the direct costs of managing advanced heart failure and VAD therapy in a quaternary 
specialist heart failure centre? 
4. Could proxy quality of life assessments provided by clinicians for their heart failure patients 
provide useful utility estimates? 
 xxiv  
Four studies were undertaken, and a brief statement of findings is given below. 
 Study 1: Methods: 
Linked administrative data provides a useful adjunct source for imputing costs external to the 
implanting centre, and combined with institutional data can illuminate both the pathways to transplant 
referral and the hospital activity generated by patients experiencing the terminal phases of heart failure 
in the year prior to transplant, cf-VAD implant or death. 
 Study 2: Hospitalisation: 
Higher pre-implant hospitalisation in VAD patients reflects higher clinical acuity and implant is 
significantly associated with reduced admissions, and hospitalisation once reconditioning has occurred. 
 Study 3: Costs: 
Once discharged home VAD implant stabilises hospital costs compared with accelerating costs in the 
year preceding implant. A high proportion of the hospital costs in the pre-implant year occur outside the 
implanting centre and should be considered in economic models assessing the impact of VAD implant. 
 Study 4: Proxy Quality of Life: 
Clinicians in our sample tend to overestimate prQoL in heart failure patients, with patient sex, 
depressed mood and measured frailty all worsening the inter rater gap 
1.9.2 Implications for policy, practice, education and research. 
This thesis has shown the power of data to enrich clinical decision-making, as well as ensure policy and 
funding decisions are strategic, evidence based and reflect the needs of patients, families, communities, 
and clinicians. Progressing value-based health care remains a challenge requiring a commitment to 
rigorous studies within the framework of economic evaluation. In establishing the comparator 
populations, future cost effectiveness studies investigating VADs in advanced heart failure, should 
consider the costs and hospitalisations accrued at institutions other than the implanting centre. Formal 
screening for quality of life in this cohort would support reimbursement decisions and enhance shared 
decision-making in heart failure with real world patient reported outcomes data. Such data could impact 
patient selection, pre- conditioning pathways and the timing of implantation which could all impact the 
cost and effectiveness of ventricular assist device therapy in advanced heart failure. 
  
